Y-mAbs Therapeutics (YMAB) Stock Rating Upgraded by Zacks Investment Research
According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
Separately, HC Wainwright set a $36.00 price target on Y-mAbs Therapeutics and gave the stock a buy rating in a research report on Tuesday, May 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $30.00.
Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.11). Research analysts forecast that Y-mAbs Therapeutics will post -1.95 EPS for the current fiscal year.
In other Y-mAbs Therapeutics news, insider Thomas Gad sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $20.03, for a total transaction of $80,120.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 266,000 shares of company stock worth $6,797,540 in the last ninety days.
Several large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA acquired a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $38,000. Citigroup Inc. acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $37,000. Strs Ohio acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $38,000. New York State Common Retirement Fund acquired a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $63,000. Finally, TD Asset Management Inc. increased its holdings in shares of Y-mAbs Therapeutics by 24.1% during the 1st quarter. TD Asset Management Inc. now owns 22,829 shares of the company’s stock worth $598,000 after acquiring an additional 4,432 shares during the last quarter. 24.80% of the stock is currently owned by hedge funds and other institutional investors.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.